Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 8 July 2024 AM
Last week, the TGA approved three new drugs including Novo Nordisk's game-changing weekly insulin injection Awiqli.
It is indicated for the treatment of type 2 diabetes in adults and type 1 diabetes in adults in conjunction with a bolus insulin, where daily basal insulin injections are not suitable.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.